Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764587 | 0.98 | LPAR3 (0.55) | LPAR3LPAR2LPAR1PLA2G2ACES2 | |
| SCHEMBL21764714 | 0.93 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL21764799 | 0.85 | LPAR3 (0.36) | LPAR3LPAR2LPAR1PLA2G2ALPAR5 | |
| SCHEMBL27973622 | 0.78 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL12555188 | 0.76 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL1139886 | 0.76 | LPAR3 (0.59) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL16996796 | 0.76 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CES2LPAR5 | |
| SCHEMBL16996793 | 0.76 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CES2LPAR5 | |
| SCHEMBL16996791 | 0.76 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CES2LPAR5 | |
| SCHEMBL17860954 | 0.76 | CYP3A4 (0.50) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | LPAR3 3397/4885LPAR2 3576/4885LPAR1 3108/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | LPAR3 1324/4885LPAR2 1258/4885LPAR1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.